





Fax Completed Form To 1.833.404.2392 Prescriber Help Desk

Prescriber Help Desk 1.833.587.2012

Online

covermymeds.com/main/ prior-authorization-forms/

Request for Prior Authorization ANTIEMETIC-5HT3 RECEPTOR ANTAGONISTS/ SUBSTANCE P NEUROKININ PRODUCTS

(PLEASE PRINT – ACCURACY IS IMPORTANT)

(122/02/1/07/1/1/1/1/1/1/1/1/1/1/1/1/1/1/1/1/1/		
IA Medicaid Member ID #	Patient name	DOB
Patient address		
Provider NPI	Prescriber name	Phone
Prescriber address Fax		
Pharmacy name	Address	Phone
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.		
Pharmacy NPI		IDC
medications for quantities exceeding the dosage limits provided in parentheses. Payment for Antiemetic-5HT3 Receptor Agonists/Substance P Neurokinin Agents beyond this limit will be considered on an individual basis after review of submitted documentation. Prior authorization will be required for all non-preferred Antiemetic-5HT3 Receptor Antagonists/ Substance P Neurokinin medications beginning the first day of therapy. Payment for non-preferred medications will be authorized only for cases in which there is documentation of previous trial(s) and therapy failure with a preferred agent in this class. Note: Aprepitant (Emend®) will only be payable when used in combination with other antiemetic agents (5-HT3 medication and dexamethasone) for patients receiving highly emetogenic cancer chemotherapy.		
Preferred Non Preferred □ Emend 80mg capsules (8) □ Akynzeo (2) □ Sancuso Patch □ Emend 125mg capsules (4) □ Aloxi 0.25mg/5mL (4 vials) □ Zuplenz □ Ondansetron 4mg tablets (60) □ Anzemet 50mg & 100mg tablets (5) □ Anzemet 100mg/5mL (4 vials) □ Ondansetron 2mg/mL (4 - 20mL vials) □ Anzemet 12.5mg/0.625mL (8 ampules) □ Ondansetron 2mg/mL (8 - 2mL vials) □ Aprepitant □ Ondansetron ODT 4mg tablets (60) □ Emend Oral Suspension □ Ondansetron ODT 8mg tablets (60) □ Granisetron 1mg tablets (8) □ Ondansetron oral solution 4mg/5mL (50mL/month) □ Granisetron 4mg/4mL (2 vials)		
	Dosage Instructions Quantity	Days Supply
Diagnosis:		
Medical reasoning for therapy exceeding dosage limits:		
Reason for use of Non-Preferred drug requiring prior approval:		
Prescriber signature (Must match prescri	ber listed above.)	Date of submission

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Health and Human Services, that the member continues to be eligible for Medicaid.